Department of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu District, Changsha, Hunan, 410008, China.
Department of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu District, Changsha, Hunan, 410008, China.
Drug Metab Pharmacokinet. 2019 Oct;34(5):340-349. doi: 10.1016/j.dmpk.2019.07.004. Epub 2019 Aug 2.
The present study aims is to investigate the metabolic mechanism of Xue-Fu-Zhu-Yu decoction (XFZYD) in the treatment of blood-stasis syndrome in Coronary Heart Disease (CHD). To that end, 30 CHD patients with Blood-Stasis Syndrome (BSS) and 20 healthy subjects were enrolled. LC-Q-TOF/MS analysis determined that in comparison between CHD with BSS patients (Group A) and healthy subjects (Group C), 59 significantly differential metabolites in the positive mode and 18 significantly differential metabolites in the negative mode. The metabolite constituents in the plasma of 30 CHD with BSS patients before (group A) and after 30 days of treatment (Group B), and 20 healthy subjects (Group C) were analyzed using LC-Q-TOF/MS and GC-MS. Based on multivariate statistical analysis (PCA, PLS-DA and OPLS-DA), we determined 69 differential metabolites. The levels of hemorheology indexes were significantly down-regulated after treatment. Metabolic pathway attribution analysis showed that lipid metabolism, amino acid metabolism and bile acid metabolism pathways are involved. Our study identifies the metabolic networks of CHD and demonstrates the efficacy of this metabolomics approach to systematically study the therapeutic effect of XFZYC on CHD.
本研究旨在探讨血府逐瘀汤（XFZYD）治疗冠心病血瘀证的代谢机制。为此，纳入 30 例冠心病血瘀证（BSS）患者和 20 例健康对照者。LC-Q-TOF/MS 分析确定，与冠心病血瘀证患者（A 组）和健康对照者（C 组）相比，正模式下有 59 个显著差异代谢物，负模式下有 18 个显著差异代谢物。采用 LC-Q-TOF/MS 和 GC-MS 分析 30 例冠心病血瘀证患者治疗前（A 组）和治疗 30 天后（B 组）及 20 例健康对照者（C 组）的血浆代谢产物。基于多元统计分析（PCA、PLS-DA 和 OPLS-DA），确定了 69 个差异代谢物。治疗后血液流变学指标水平显著下调。代谢途径归属分析表明，涉及脂质代谢、氨基酸代谢和胆汁酸代谢途径。本研究鉴定了冠心病的代谢网络，并证明了代谢组学方法在系统研究 XFZYC 对冠心病的治疗效果方面的有效性。
